Psoriasis is more than just a skin condition. It is a complex, incurable systemic immune disease that is associated with psychosocial impairments, high levels of suffering and often one or more comorbidities.

One inflammation leads to the next

The inflammatory processes usually affect more than just the skin. There is often a domino effect with far-reaching consequences for the whole body. The most common comorbidities of psoriasis include joint inflammation (arthritis), cardiovascular disease, type 2 diabetes mellitus and depression. The risk of being affected by a comorbidity increases with the severity of the psoriasis.

Early treatment can stop the wave

With modern therapies, psoriasis can be well controlled in the vast majority of patients. However, drug therapies, e.g. with interleukin inhibitors, are often very expensive and not accessible to all of the approximately 60 million people affected worldwide. Biosimilars can help to close these gaps in treatment by making established active ingredients available in high quality and at a lower cost.

Formycon, as a pure-play biosimilar developer, is committed to the mission of improving access to such modern therapy options worldwide. In the case of psoriasis, specifically with the ustekinumab biosimilar FYB202.

Find out more about World Posriasis Day at: https://www.ifpa-pso.com/global-actions-overview/world-psoriasis-day